Objective-The assembly of a functional vascular system requires a coordinated and dynamic transition from activation to maturation. High vascular endothelial growth factor activity promotes activation, including junction destabilization and cell motility. Maturation involves junctional stabilization and formation of a functional endothelial barrier. The identity and mechanism of action of prostabilization signals are still mostly unknown. Bone morphogenetic protein receptors and their ligands have important functions during embryonic vessel assembly and maturation. Previous work has suggested a role for growth differentiation factor 6 (GDF6; bone morphogenetic protein 13) in vascular integrity although GDF6's mechanism of action was not clear. Therefore, we sought to further explore the requirement for GDF6 in vascular stabilization. Approach and Results-We investigated the role of GDF6 in promoting endothelial vascular integrity in vivo in zebrafish and in cultured human umbilical vein endothelial cells in vitro. We report that GDF6 promotes vascular integrity by counteracting vascular endothelial growth factor activity. GDF6-deficient endothelium has increased vascular endothelial growth factor signaling, increased vascular endothelial-cadherin Y658 phosphorylation, vascular endothelial-cadherin delocalization from cell-cell interfaces, and weakened endothelial cell adherence junctions that become prone to vascular leak. 
T he complex body design of vertebrates requires efficient transport of gases, liquids, nutrients, and circulating cells between tissues and organs. This task is performed by the highly branched cardiovascular system. Endothelial cells line the lumen of blood vessels and form a semipermeable monolayer that controls blood-tissue fluid and nutrient exchange. The integrity of the endothelial barrier is essential for physiological tissue homeostasis, and hyperpermeability is involved in the progression of several pathological conditions, including inflammation, atherosclerosis, and cancer. 1 During development, the vascular network is formed mainly by angiogenesis-the formation of new blood vessels from pre-existing ones. In conditions that favor angiogenesis, some endothelial cells respond to vascular endothelial growth factor (VEGF) cues by loosening their connections with neighboring cells and becoming invasive and migratory. 2 The zebrafish embryo provides a useful model system for studying these complex cellular behaviors because it enables visualization of the vascular network in vivo in a developing embryo. As we have described previously, 3 intersegmental vessels emerge from the dorsal aorta (DA) starting at ≈20 hpf, migrating dorsally along the somite boundaries in response to VEGF and other cues. At 32 hpf, ≈12 hours after initial intersegmental vessel sprouting, intersegmental vessel tip cells approach each other to fuse and form the dorsal longitudinal anastomotic vessel. Over the course of the following 18 hours, the system stabilizes, forming continuous lumens throughout, and greatly reducing endothelial cell protrusive activity. This maturation phase may be controlled by prostabilization signals that counteract VEGF activity, leading to adherence junction (AJ) stabilization and formation of functional barrier. However, the identity and mechanism of action of prostabilization signals are still unknown.
A variety of genetic and experimental data suggest that BMP (bone morphogenetic protein) signaling has a crucial role in maintaining vascular integrity. [4] [5] [6] [7] Growth differentiation factor 6 (GDF6; BMP13) is a BMP family member belonging to the growth differentiation factor subgroup. The amino acid sequence for GDF6 (BMP13) is highly conserved across vertebrates, with sequence homology concentrated in the active C-terminal domain. Even the most divergent of BMP13-homologues, Zebrafish gdf6a (radar) and gdf6b (dynamo), display >90% homology in this domain. 8 The role of GDF6 is probably best understood in regulating bone and ocular development across several species, including humans. Patients with mutations in the GDF6 gene, such as those noted in Klippel-Feil syndrome, can phenotypically present with fusion of the vertebrae and limited mobility in addition to having several ocular disorders. 9, 10 Ocular disorders known to be linked to mutations in GDF6 include microphthalmia, coloboma, and age-related macular degeneration. [11] [12] [13] [14] [15] An age-related macular degeneration risk allele linked to GDF6 is also associated with increased expression of HTRA1 (HtrA serine peptidase 1), and HTRA1 knockout mice show decreased vascular development in the retina together with increased GDF6 and decreased VEGFA expression. 15 A previous report using morpholino knockdown suggested a role for gdf6a in establishment of trunk vasculature integrity in the zebrafish. 16 However, the precise mechanism by which gdf6a regulates vascular integrity is unclear and is the focus of this study.
AJs and the key AJ component vascular endothelial-cadherin (VECDN) in particular play an important role in the control of vascular permeability and integrity. 17, 18 Barrierdestabilizing agents, such as VEGF, can induce increases in vascular permeability through modulation of the activity of different small GTPases. VEGF stimulation of endothelial cells activates Src, which stimulates Vav2, Rac1, and its downstream effector PAK1 (p21 [RAC1]-activated kinase 1). In turn, PAK1 phosphorylates a serine residue (Ser665) in the cytoplasmic tail of VECDN, thereby promoting its endocytosis and increasing the vascular permeability. 19 More recently, c-SRC-dependent phosphorylation of VECDN at Tyr658 was found to induce uncoupling of p120-catenin from VECDN, resulting in internalization of VECDN from AJs and subsequent loss of endothelial barrier function. 20 In this study, we report a previously uncharacterized trunk hemorrhage phenotype in gdf6a s327 zebrafish mutants and examine the consequences of GDF6 loss of function for endothelial cells in vivo and in vitro. We find that GDF6 is required for proper endothelial barrier function and that it acts as a negative regulator of VEGF receptor 2 (VEGFR2) receptor levels and VEGF signaling. In addition to increased receptor levels, GDF6-deficient endothelial cells show increased downstream ERK (mitogen-activated protein kinase 1) activation and increased phosphorylation, destabilization, and internalization of VECDN. Together, our results suggest that GDF6 function promotes vascular quiescence and endothelial barrier function by restraining VEGF signaling-dependent junction destabilization.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

GDF6 Loss-of-Function Results in Impaired Vascular Structural Integrity and Increased Vascular Permeability
Zebrafish have 2 GDF6 orthologs, gdf6a and gdf6b. However, whole-mount in situ hybridization reveals that gdf6a is the sole GDF6 player expressed in the zebrafish trunk at 48 hpf ( Figure 1A-1C) , so we focused on this gene for our analysis. At 48 hpf, gdf6a is expressed in endothelial cells of the axial vasculature (DA and posterior cardinal vein) and in the dorsal fin fold adjacent to the newly formed dorsal longitudinal anastomotic vessel ( Figure 1B) . To investigate the role of gdf6a in vascular integrity, we examined zebrafish carrying the gdf6a s327 mutation. This mutation results in a single C to A substitution in position 164 of the gdf6a-coding sequence, introducing a stop codon early in the gdf6a open reading frame. 13 The mutant allele is predicted to encode a truncated proprotein of 54 amino acids lacking the putative C-terminal mature signal peptide. As previously reported, mutants develop on a comparable schedule compared with their wild-type siblings ( Figure 1D and 1E ), but they display microphthalmia and melanocyte mispatterning ( Figure 1F and 1G ). In addition, we find that 25% of gdf6a s327 mutants also develop trunk hemorrhage ( Figure 1G-1N ). The hemorrhages gradually clear for the next 2 days of development, and 90% of hemorrhaging mutants are homozygous viable. The hemorrhage phenotype could be phenocopied by gdf6a morpholino knock down, with 24% of embryos injected with 5 ng of gdf6a 5′ splice blocking morpholino developing trunk hemorrhage at 48 hpf ( Figure 1O and 1P) .
To better understand the effects of loss of gdf6a on trunk endothelial barrier function, we analyzed vascular patterning and stability in gdf6a mutants. In severe cases of massive hemorrhage, we found evidence for impaired vascular structural integrity around the lesion site ( Figure 1I-1N ). However, in nonhemorrhaging mutants or mutants with small hemorrhages, the pattern and morphology of trunk vessels did not seem significantly affected, suggesting that vessel malformation is not a primary defect in gdf6a s327 mutants. In addition, vascular outgrowth and intersegmental vessel formation seem normal before the onset of the hemorrhage phenotype ( Figure 1D and 1E Figure 1Q-1W ). These results suggest that vascular barrier dysfunction is present in a large majority of gdf6a s327 mutants despite the fact that obvious large-scale vascular rupture (hemorrhage) occurs in only 25% of mutants.
To further support the idea that the effects on vascular barrier function in gdf6a s327 mutants are a direct consequence of loss of gdf6a, we used inducible expression of wild-type gdf6a to rescue the hemorrhage phenotype in mutants. Because gdf6a is maternally deposited and plays a crucial role in early dorsal-ventral patterning, 21 we used heat shock-inducible expression of gdf6a-2a-mcherry transgene with induction starting at 32 hpf to avoid effects on early embryonic patterning. The hemorrhage phenotype was rescued by heat shockinducible gdf6a expression, with the frequency of hemorrhage dropping from 33% in control mcherry transgene-injected gdf6a s327 embryos to 8% in gdf6a-2a-mcherry transgeneinjected animals ( Figure 1X ).
GDF6 expression is also present in human endothelial cells, including human umbilical vein endothelial cells (HUVEC), as revealed by reverse transcription polymerase chain reaction analysis. To test whether the role of GDF6 in promoting endothelial barrier function is evolutionarily conserved, we knocked down GDF6 in HUVEC cells using small interfering RNA (siRNA; Figure 2A and 2B) and then subjected GDF6 or control siRNA-treated HUVEC to a transwell dye leakage vascular permeability assay ( Figure 2C ). Assembly of an endothelial monolayer from control siRNA-treated HUVEC (Control siRNA) reduced transwell permeability to <20% of that present in the absence of cells (No Cell Control) while assembly of an endothelial monolayer from GDF6 siRNA-treated HUVEC (GDF6 siRNA) resulted in a 2.5-fold increase in transwell permeability compared with the control siRNA-treated cell monolayer (to 50% of the No Cell Control; Figure 2D ). The increased permeability noted in GDF6 siRNA conditions could be largely or completely reversed by either administration of recombinant GDF6 protein or depletion of VEGFA ligand from the assay using an anti-VEGFA neutralizing antibody ( Figure 2D ). As positive and negative controls for this assay, addition of recombinant VEGFA protein or sphingosine-1-phosphate to HUVEC monolayers resulted in increased or decreased permeability, respectively ( Figure 2E ). These results support a crucial role for GDF6 as a prostabilization cue and a potential role for GDF6/VEGF signaling in regulation of endothelial cell-cell junctions.
GDF6 Loss-of-Function Results in Increased VEGF Signaling in Endothelial Cells
Our results show that loss of GDF6 results in endothelial barrier dysfunction but that removal of VEGFA from the system can rescue this phenotype ( Figure 2D ). We hypothesize that GDF6 might stabilize the developing vasculature by counteracting the effects of VEGF signaling, with loss of GDF6 resulting in a disregulated angiogenic balance tipped toward the activation state. VEGF signals through VEGFR2 to activate endothelial cells. Activation of VEGFR2 results in phosphorylation of several residues in the VEGFR2 cytoplasmic tail, 22 including Tyr1175, whose phosphorylation leads to ERK activation that in turn increases cell motility and decreases stability ( Figure 3A) . 23, 24 We examined the levels of total and Tyr1175-phosphorylated VEGFR2 protein in control or GDF6 siRNA-treated HUVEC using Western blotting and found that GDF6 knockdown results in an Figure 2 . Loss of growth differentiation factor 6 (GDF6) function results in impaired vascular integrity in vitro. A, Reverse transcription polymerase chain reaction (PCR) of GDF6 and glyceraldehyde-3-phosphate dehydrogenase (G3PDH; loading control) from human umbilical vein endothelial cell (HUVECs) that were treated with either control small interfering RNA (siRNA; Control, column 1) or 1 of 2 different siRNAs targeting GDF6 (GDF6 #1 and GDF6 #2, columns 2 and 3). Both GDF6-targeting siRNAs knocked down GDF6 transcript levels, but siRNA #2 was much more effective. Observation noted from 3 independent experiments. B, TaqMan assay quantification of GDF6 transcript levels in control or GDF6 siRNA-treated HUVEC cells (both siRNAs were used in tandem to ensure maximal gene suppression efficiency for all experiments), showing >90% reduction in GDF6 transcript levels in GDF6 siRNA-treated HUVEC. C, Schematic diagram illustrating the HUVEC monolayer permeability assay. Briefly, HUVECs are seeded in the inner well of a transwell chamber in complete growth medium (i). The cells attach to the membrane and form cell-cell adhesions, assembling a confluent monolayer on the membrane before dye addition (ii). Fluorescein isothiocyanate (FITC)-dextran is added to the inner well of the transwell chamber, remaining largely contained within the inner chamber when cell-cell adhesion is intact (iii). Defects in endothelial cell-cell adhesion result in increased permeability across the monolayer and increased FITC-dextran leakage into the outer, plate well. The intensity of fluorescence in the outer well is proportional to the extent of monolayer permeability (iv). D, Quantification of the amount of FITC transferred through a HUVEC monolayer, expressed as a percentage of the amount of dye that transfers across the membrane in the absence of any added HUVEC cells (ie, no cell control). A control siRNA-treated HUVEC monolayer reduces FITC transfer to ≈10% of the no cell condition, but treating HUVEC with GDF6 siRNA results in a 3.5-fold increase in permeability. Treatment with either soluble GDF6 protein or anti-vascular endothelial growth factor (VEGF) A antibody reduces the increased permeability caused by GDF6 siRNA knockdown. Equivalent results noted in 3 separate experiments. E, Quantification of the amount of FITC transferred through the HUVEC monolayer, expressed as a percentage of the amount of dye that transfers across the membrane with a control HUVEC monolayer. VEGFA treatment results in increased monolayer permeability while sphingosine-1-phosphate (S1P) treatment results in decreased monolayer permeability. Quantitative PCR data (B) were collected from at least 3 biological repeats with 3 technical repeats per probe. Permeability assays (D and E) were done as 3 biological replicates with at least 3 technical repeats per each experimental condition. Data were shown from a single biological replicate.
≈2-fold increase in both Tyr1175-phosphorylated and total levels of VEGFR2 ( Figure 3B and 3C) . The proportional increase in total-and phospho-VEGFR2 levels suggests that the increase in Tyr1175-phosphorylated VEGFR2 can be attributed mainly to an increase in the total receptor levels. The increase in total VEGFR2 protein levels could be partially rescued by the readministration of recombinant GDF6 protein to the HUVEC growth media ( Figure 3D ). Next, we quantified VEGFR2 mRNA transcript levels in control or GDF6 siRNA-treated HUVEC by quantitative reverse transcription polymerase chain reaction analysis. We found that that GDF6 knockdown in HUVECs results in an ≈3.5-fold increase in VEGFR2 transcript levels ( Figure 3E ). Total VEGFR2 transcript levels are also increased in gdf6a s327 mutants in vivo as assessed by both quantitative reverse transcription polymerase chain reaction ( Figure 3F ) and by whole-mount in situ hybridization ( Figure 3G and 3H) although not to as great an extent as in knockdown HUVEC in vitro. Together, these results suggest that loss of GDF6 function results in increased expression and accumulation of VEGFR2 receptor.
To examine whether signaling downstream from the VEGFR2 receptor was also increased, we examined the phosphorylation of ERK1/2. As noted above, VEGFR2 receptor phosphorylation triggers phosphorylation or ERK, which in turn promotes increased endothelial motility and decreased stability ( Figure 3A) . We examined the levels of both total and Thr202/ Tyr205-phosphorylated 25 ERK1/2 protein in control or GDF6 siRNA-treated HUVEC using Western blotting and found that GDF6 knockdown results in an ≈1.6-fold increase in phospho-ERK1/2 without altering total protein levels ( Figure 4A and 4B). Measurement of endothelial phospho-ERK was also performed in gdf6a s327 mutants by quantifying ERK activation in the trunk axial vessels of phospho-ERK1/2 immunostained mutants versus their wild-type siblings ( Figure 4C-4G) , showing a 2.3-fold increase in phospho-ERK1/2 in gdf6a s327 mutants. Together, these results suggest that GDF6 functions to restrain VEGFR2 levels and VEGF signaling. , which in turn promotes increased endothelial cell motility and proliferation. B, Representative images of Western blots used to measure levels of phospho (Tyr 1175) VEGFR2 or total VEGFR2 protein vs an α-tubulin loading control, using extracts from either control small interfering RNA (siRNA)-or GDF6 siRNA-treated human umbilical vein endothelial cell (HUVEC) in vitro. C, Quantification of phospho (Tyr 1175) VEGFR2 and total VEGFR2 protein levels normalized to α-tubulin loading controls, using extracts from either control siRNA-or GDF6 siRNA-treated HUVEC in vitro. Protein levels are expressed as percentages of control siRNA-treated amounts. D, Quantification of total VEGFR2 protein levels in control siRNA-or GDF6 siRNA-treated HUVEC treated with either nothing or with recombinant GDF6 protein, normalized to α-tubulin loading controls. Protein levels are expressed as percentages of control siRNA-treated amounts. E, TaqMan assay quantification of VEGFR2 transcript levels in control or GDF6 siRNA-treated HUVEC cells, showing an ≈3.5-fold increase in VEGFR2 transcript levels in GDF6 siRNA-treated HUVEC. F, TaqMan assay quantification of VEGFR2 transcript levels in the trunks of 36 hpf wild-type (WT) sibling or gdf6as 327 mutant animals, showing a 1.6-fold increase in vegfr2 transcript levels. Whole-mount in situ hybridization (WM-ISH) of the midtrunk of 36 dpf wild-type sibling (G) and gdf6as 327 mutant (H) animals probed for vegfr2, showing increased vascular expression. Images are lateral views, rostral to the left. Scale bar, 50 µm. Western blot results are shown from 2 to 3 independent biological repeats. Protein lysates from each biological repeat were blotted twice for each antibody (2 technical repeats). Quantitative polymerase chain reaction data were collected from at least 3 biological repeats with 3 technical repeats per probe. WM-ISH was performed in 3 biological replicates with at least 10 embryos per experimental group.
GDF6 Loss-of-Function Results in Defective Endothelial Cell-Cell Junction Formation
Elevated VEGF signaling is associated with increased permeability and decreased barrier function in the endotheliumindeed, VEGF was originally identified as vascular permeability factor based on its ability to induce vascular leakage. 26 These effects are due, in part, to both destabilization of endothelial cell-cell junctions and increased transendothelial transport. 1 VEGF-induced fenestration allows leakage of small solutes, and passage of proteins has been attributed to VEGF-induced formation of caveolae, assembly of caveolae into vesiculovacuolar organelles, and induction of transendothelial pores. 27, 28 Leakage of larger proteins and extravasation of red blood cells depend on VECDN-mediated loosening of AJs, which allows passage between endothelial cells. 1 We examined the ultrastructure of blood vessels and endothelial cell junctions in gdf6a s327 mutants and their wild-type siblings to determine whether mutant endothelium exhibits some of the characteristics noted above.
We performed electron microscopy on transverse sections of the midtrunk of 48 hpf zebrafish gdf6a s327 mutant or wildtype sibling animals to assess vascular endothelial cell morphology and ultrastructure. The gross morphology of mutants was substantially normal, and both axial vessels (DA and cardinal vein) were clearly evident in both wild-type and mutant animals. Electron micrographs of the endothelial lining of the DA revealed a single endothelial cell layer in either gdf6a s327 mutant or wild-type sibling animals ( Figure 5A-5H) . In wildtype siblings, endothelial cell-cell junctions were clearly visible on the DA (Figure 5A-5D ). These wild-type junctions generally showed closely apposed cell membranes with numerous electron-dense areas on and near cell-cell interfaces (red arrows in Figure 5B and 5D) . Endothelial cell-cell junctions were also readily visualized on the DA in gdf6a s327 mutants, but they often appeared less well developed, displaying less closely apposed membranes and fewer junctional electron-dense areas ( Figure 5E-5H) . Quantitative measurement of the average length of DA junctions in gdf6a s327 mutants compared with their wild-type siblings showed that junctions are on average substantially shorter in mutants than in wild-type animals ( Figure 5I ). gdf6 loss of function has been linked to an increase in apoptosis of tissue in the developing eye.
14 To rule out increased cell death, Caspase 3 staining was performed on gdf6a s327 mutants and their wild-type siblings, revealing no increase in the number of apoptotic ECs in the DA before the onset of hemorrhage (Figure 5J-5M) . Together, these results confirm that failure to counteract VEGF signaling with GDF6 leads to ultrastructurally apparent defects in endothelial cell-cell junctions without an apparent increase in endothelial cell death.
GDF6 Loss-of-Function Results in Increased VECDN Internalization and Degradation
AJs, and the AJ key component VECDN in particular, play an important role in the control of vascular permeability and integrity. 17, 18, 29 As noted above, VEGF is a well-known permeability-inducing agent. VEGF activation is known to initiate an intracellular cascade of events that leads to phosphorylation of VECDN on tyrosine 658, promoting VECDN internalization and degradation, ultimately increasing transendothelial permeability ( Figure 6A ; 20, 30, 31 ). To test whether in vivo loss of GDF6 results in VECDN destabilization, we began by using Western blotting to examine the total levels of VECDN protein in hemorrhaging or nonhemorrhaging zebrafish gdf6a s327 mutants compared with their wild-type siblings ( Figure 6B and 6C) . We found that gdf6a s327 mutants have 35% to 40% less VECDN protein than wild-type siblings, with similar VECDN protein levels in gdf6a s327 mutants with and without visible hemorrhage. We also examined levels of both total and phospho-VECDN (Tyr658) in control and GDF6 siRNA-treated HUVEC in vitro by Western blotting (Figure 6D and 6E) . Although GDF6 loss of function in HUVEC did not lead to significant reduction in levels of total VECDN, phospho-VECDN levels were substantially increased, suggesting that VECDN is being destabilized in GDF6-deficient endothelial cells. To further examine the role of GDF6 in endothelial junction formation, we use immunofluorescence to examine PECAM1 (platelet and endothelial cell adhesion molecule 1), total VECDN, and phospho-VECDN localization in control or GDF6 siRNA-treated HUVEC forming an endothelial monolayer in culture. GDF6-deficient HUVEC showed reduced PECAM1 and VECDN localization at endothelial cell-cell interfaces but strong phospho-VECDN staining of residual junctions ( Figure 6F-6O) , confirming that junction disassembly occurs in the absence of GDF6. Treatment of control HUVECs with VEGFA ligand or sphingosine-1-phosphate was used as positive and negative controls for junctional assembly. Treatment with VEGFA resulted in decreased VECDN localization at endothelial cell-cell interfaces and high levels of phospho-VECDN staining of residual junctions whereas treatment with sphingosine-1-phosphate showed the opposite effects ( Figure 6P-6U ).
Discussion
Together, our results suggest that GDF6 functions to antagonize VEGF-mediated phosphorylation of VECDN by reducing VEGFR2 receptor levels, preventing destabilization, internalization, and degradation of VECDN, and promoting junctional stability and vascular integrity ( Figure 6V ). In line with these observations, we showed recently that partial reduction of zebrafish VECDN expression using low doses of morpholinos causes vascular fragility, hemorrhage, and increased trunk vessel permeability. 32 Interestingly, VECDN also seems to alter transforming growth factor β (TGF-β) signaling in the endothelium, with VECDN regulating VEGF/ ERK1/2 and TGF-β/Smad signaling pathways in opposite ways with identical biological outcomes in endothelial cells. 33 The formation of a VECDN-VEGFR2 complex limits cell proliferation by preventing ERK1/2 activation 34 whereas formation of VECDN-TGF-β receptor complexes promotes TGF-β-induced Smad2/3 phosphorylation leading to vascular stabilization. 33 A proquiescence role has also been described mutants, or gdf6as 327 mutants with trunk hemorrhage. C, Quantification of total VECDN protein levels normalized to α-tubulin loading controls, using protein extracts from WT siblings, nonhemorrhaging gdf6as 327 mutants, or gdf6as 327 mutants with trunk hemorrhage. D, Representative images of Western blots used to measure levels of phospho-VECDN (Y658) or total VECDN protein vs an α-tubulin loading control, using protein extracts from human umbilical vein endothelial cells (HUVEC) treated with either control siRNA or 1 of 2 different GDF6 small interfering RNA (siRNAs). E, Quantification of phospho-VECDN (Y658) or total VECDN protein levels normalized to an α-tubulin loading control, using protein extracts from HUVEC cells treated with either control siRNA or 1 of 2 different GDF6 siRNAs. Protein levels are expressed as fractions of control siRNA-treated amounts. Representative confocal images of control (F-J) or GDF6 (K-O) siRNA-treated HUVECs in endothelial monolayers, subjected to immunofluorescence staining using antibodies against PECAM1 (platelet and endothelial cell adhesion molecule 1; gray; F and K), total VECDN (red; G, I, L, and N, and phospho-VECDN (Y658; green; H, J, M, and O). H, J, M, and O, Magnified views of the boxed regions in G, I, L, and N, respectively. PECAM1 and VECDN images show reduced cell-cell junctional staining in GDF6 siRNA-treated HUVEC but strong phospho-VECDN (Y658) staining of some of the remaining junctions. Representative confocal images of control HUVECs in endothelial monolayers treated with nothing (P and Q), VEGFA recombinant protein (R and S), or sphingosine-1-phosphate (S1P; T and U) overnight then subjected to immunofluorescence staining using antibodies against total VECDN (red; P-U) and phospho-VECDN (Y658; green; Q, S, and U). Merged images of phospho-VECDN (Y658) and total VECDN (Q, S, and U) show their relative localization patterns. Western blot results are shown from at least 2 independent biological repeats. Protein lysates from each biological repeat were blotted twice for each antibody (2 technical repeats). Immuostaining assays were done as at least 2 biological replicates with a minimum or 2 technical replicates per each experimental condition, and 5 images analyzed per replicate. V, Model for the role of GDF6 in endothelial barrier formation. GDF6 activity restrains VEGF activity, promoting endothelial junction stabilization. GDF6 loss-of-function (LOF) results in increased VEGF signaling, increased VECDN phosphorylation, internalization, and degradation, and reduced endothelial barrier function. VEGFR2 indicates VEGF receptor 2.
for other BMP superfamily members, including BMP9 and BMP10. BMP type II receptor 2 (BMPR2) was found to form a signaling complex with activin receptor-like kinase 1 (ALK1/ACTVRL1) and signal specifically in response to BMP9/10 in microvascular endothelial cells. 35 Unlike other BMPs, BMP9 circulates at measureable concentrations in serum and is thought to act as a vascular quiescence factor, blocking angiogenesis in vitro 36 and in vivo, 35, 37 making it a candidate for therapeutically targeting the dysfunctional pulmonary endothelium in patients with pulmonary arterial hypertension. 38 Mutations in BMPR2 and ALK1 are associated with pulmonary arterial hypertension. 39, 40 Moreover, Li et al 7 showed that in adult mice, stably silencing BMPR2 expression by RNA interference results in severe mucosal hemorrhage and incomplete mural cell coverage of vessel walls. Interestingly, pulmonary artery endothelial cell from Bmpr2(+/−) mice have a constitutively active SRC kinase, an increased number of caveolae, and impaired endothelial barrier function. 41 Our results suggest that the cause of some of these phenotypes may be misregulated VEGF signaling activity rather than action on direct downstream targets of BMP signaling. The involvement of additional signaling pathways in the pathophysiology of BMP-related vascular diseases would open new therapeutic horizons for these disorders.
The link between GDF6 and modulation of the VEGF receptor still remains to be determined. The specific receptors transducing GDF6 activity are still unclear although GDF6 has a demonstrated preferential affinity for BMPR1B (ALK6) and BMPR2. 42 In a rat osteoblast cell line (ROB-C26), GDF6 forms complexes with BMPR1B and BMPR2 to transduce a strong transcription initiation signal as measured by the use of a luciferase reporter gene with the 3TP promoter that contains 3 consecutive TPA (12-O-tetradecanoylphorbol-13-acetate) response elements and a portion of the plasminogen activator inhibitor 1 promoter region. A weaker signal and barely detectable receptor complex are associated with BMPR1A (ALK3)/BMPR2 (Erlacher et al 42 ) . The receptors and downstream signaling pathways used by GDF6 in endothelial cells need to be examined further, however. Together, our results and previous studies on the function of TGF β and BMP family members in the vasculature suggest complex roles in regulating vascular quiescence and maturation.
